AGP Picks
View all

Today in Healthcare: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Healthcare.

Press releases published on July 30, 2026

Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
HUTCHMED Reports 2026 Interim Results
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Completes Patient Enrollment in Phase II Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors
Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call
Avis de conférence téléphonique de Thérapeutique Knight sur ses résultats du deuxième trimestre 2026
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Regeneron Reports Second Quarter 2026 Financial and Operating Results
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Amneal Reports Second Quarter 2026 Financial Results
Questex’s Fierce Pharma announces launch of Fierce Pharma Week Europe in Basel, Switzerland in June 2027
 Actimed Therapeutics Strengthens Board with Appointment of Dr. Anders Ullman
Relation unveils MORGAN, the next-generation model of cellular biology
Relation Announces Expanded Collaboration with GSK
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
Curium advances plans for second investment in Romania to expand access to advanced nuclear medicine

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Today in Healthcare

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.